GlassScriptPhysician profile
Ivy Derosa
NPI 1083935084
$1,016.20
in general payments reported to CMS, 2019-2025
15 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $122 · 2021: $165 · 2022: $134 · 2024: $183 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.13 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $224.32 | 2020-2021 | |
| Allergan, INC. | $173.85 | 2019 | |
| Janssen Biotech, INC. | $171.88 | 2020-2024 | Tremfya |
| Genzyme Corporation | $107.08 | 2022 | |
| Revance Therapeutics, INC. | $104.06 | 2025 | Daxxify |
| Galderma Laboratories, L.P. | $46.44 | 2019-2020 | |
| Merz North America, INC. | $35.68 | 2019-2022 | |
| Abbvie INC. | $27.56 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $26.24 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25.17 | 2019 | |
| Leo Pharma INC. | $23.16 | 2019 | |
| Pfizer INC. | $16.74 | 2021 | |
| Mayne Pharma Commercial LLC | $15.14 | 2020 | |
| Amgen INC. | $11.99 | 2022 | |
| Organon LLC | $6.89 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivy Derosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.